Zong X, Yu Y, Yang H, et al. - Researchers aimed to ascertain if ovarian impairment can be reduced in premenopausal women with breast cancer by administering gonadotropin-releasing hormone analogs (GnRHa) during chemotherapy.

• In this randomized clinical trial, 330 premenopausal women aged 18 to 49 years with operable stage I to III breast cancer were included and treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned in 2 parallel groups: treatment with chemotherapy with or without GnRHa.

• The GnRHa group and control group had a premature ovarian insufficiency rate of 10.3% vs 44.5%, respectively.

• Findings of a post hoc analysis indicated that patients younger than 35 years show improved tumor-free survival in correlation with receiving GnRHa.

• Overall, researchers recommend using gonadotropin-releasing hormone analogs to protect ovarian function in premenopausal women who are receiving chemotherapy for breast cancer.